Jie Min Luo

Chief Executive Officer bei AMOY DIAGNOSTICS CO., LTD.

41 Jahre

Health Technology

Health Services

Profil

Jie Min Luo is currently the General Manager & Director at Amoy Diagnostics Co., Ltd.
and a Member-Supervisory Board at SinoPath Medical Investment (Beijing) Co., Ltd.

Aktive Positionen von Jie Min Luo

Unternehmen	Position	Beginn
AMOY DIAGNOSTICS CO., LTD.	Chief Executive Officer	01.12.2021
SinoPath Medical Investment (Beijing) Co., Ltd. SinoPath Medical Investment (Beijing) Co., Ltd. Medical/Nursing ServicesHealth Services SinoPath Medical Investment (Beijing) Co., Ltd. engages in the third-party medical diagnostic genetics laboratory. It provides clinical genetic testing, consultation, and advisory services. Its products include cancer detection, remote pathology consultation, hereditary cancer detection, hereditary cardiovascular disease testing, single-gene genetic disease detection, susceptibility gene examination, and immunohistochemistry. The company was founded on June 30, 2013 and is headquartered in Beijing, China.	Director/Board Member	-

Alle aktiven Positionen von Jie Min Luo

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Jie Min Luo im Detail an

Beziehungen

Beziehungen ersten Grades

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Börsennotierte Unternehmen	1
AMOY DIAGNOSTICS CO., LTD.	Health Technology

Private Unternehmen	1
SinoPath Medical Investment (Beijing) Co., Ltd. SinoPath Medical Investment (Beijing) Co., Ltd. Medical/Nursing ServicesHealth Services SinoPath Medical Investment (Beijing) Co., Ltd. engages in the third-party medical diagnostic genetics laboratory. It provides clinical genetic testing, consultation, and advisory services. Its products include cancer detection, remote pathology consultation, hereditary cancer detection, hereditary cardiovascular disease testing, single-gene genetic disease detection, susceptibility gene examination, and immunohistochemistry. The company was founded on June 30, 2013 and is headquartered in Beijing, China.	Health Services